The Latisse prescribing information (bimatoprost ophthalmic solution 0.03%, for eyelash hypotrichosis) states that there are no adequate and well-controlled studies of its use in pregnant women. It also states that it is not known whether topical ocular treatment with Latisse 0.03% could produce detectable quantities in human milk.
What the Latisse prescribing information says
This section reports the Latisse label only. It is the label for Latisse (bimatoprost 0.03%). It is not the label for any other bimatoprost product.
| Question | What the source says |
|---|---|
| Are there studies in pregnant women? | The label's pregnancy risk summary states there are no adequate and well-controlled studies of Latisse 0.03% in pregnant women. |
| What does it say about birth defects and miscarriage? | The same summary states there is no increase in the risk of major birth defects or miscarriages based on bimatoprost postmarketing experience. The claim does not give the number of pregnancies behind this statement. |
| What does it say about use in pregnancy? | The label states the 0.03% product should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus. |
| What does it say about breast milk? | The label's lactation section states it is not known whether topical ocular treatment with Latisse 0.03% could result in sufficient systemic absorption to produce detectable quantities in human milk. |
Animal data in the label
The label also reports animal data. In embryofetal development studies, administration of bimatoprost to pregnant mice and rats during organogenesis resulted in abortion and early delivery at oral doses at least 33 times (mice) or 94 times (rats) the human exposure.
These are findings in animals at oral doses. The claim does not tie them to eyelid use in people.
Glaucoma medication papers cover a different use
Two papers are about medicines for glaucoma, not about eyelash treatment. A 2014 review of glaucoma in pregnancy (Curr Opin Ophthalmol) states that the risks of glaucoma medications during pregnancy are not well established for the human fetus or infant and are often inferred from animal studies. A 2024 observational multicenter descriptive survey (Eur J Ophthalmol) of topical glaucoma medications in pregnancy reports that its data suggest an overall favourable safety profile, but further investigation is needed.
Neither claim names bimatoprost or gives a concentration. They are not evidence about Latisse 0.03% used on the eyelid. Observational studies cannot show cause and effect.
What this does not tell you
This guide reports statements. It does not say whether any bimatoprost product is safe or unsafe in pregnancy or while breast-feeding. Label statements, animal data, postmarketing experience and glaucoma medication papers each answer a different question.
Every label statement here is about Latisse. None is about a compounded bimatoprost serum. The FDA states that compounded drugs are not FDA-approved, which means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. Whether any product suits a person who is pregnant, planning pregnancy or breast-feeding is a decision for a licensed provider.